326 related articles for article (PubMed ID: 15372674)
1. Use of chelating ligands to tune the reactive site of half-sandwich ruthenium(II)-arene anticancer complexes.
Fernández R; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Chemistry; 2004 Oct; 10(20):5173-9. PubMed ID: 15372674
[TBL] [Abstract][Full Text] [Related]
2. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
3. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
4. Chlorido-, aqua-, 9-ethylguanine- and 9-ethyladenine-adducts of cytotoxic ruthenium arene complexes containing O,O-chelating ligands.
Melchart M; Habtemariam A; Parsons S; Sadler PJ
J Inorg Biochem; 2007 Nov; 101(11-12):1903-12. PubMed ID: 17582501
[TBL] [Abstract][Full Text] [Related]
5. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
6. Interactions of the "piano-stool" [ruthenium(II) (eta6-arene)(en)CL]+ complexes with water and nucleobases; ab initio and DFT study.
Futera Z; Klenko J; Sponer JE; Sponer J; Burda JV
J Comput Chem; 2009 Sep; 30(12):1758-70. PubMed ID: 19090568
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
8. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
9. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate.
Wang F; Xu J; Habtemariam A; Bella J; Sadler PJ
J Am Chem Soc; 2005 Dec; 127(50):17734-43. PubMed ID: 16351102
[TBL] [Abstract][Full Text] [Related]
10. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
11. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
12. Factors that influence the antiproliferative activity of half sandwich Ru(II)-[9]aneS3 coordination compounds: activation kinetics and interaction with guanine derivatives.
Rilak A; Bratsos I; Zangrando E; Kljun J; Turel I; Bugarčić ŽD; Alessio E
Dalton Trans; 2012 Oct; 41(38):11608-18. PubMed ID: 22903512
[TBL] [Abstract][Full Text] [Related]
13. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts.
Wang F; Chen H; Parsons S; Oswald ID; Davidson JE; Sadler PJ
Chemistry; 2003 Dec; 9(23):5810-20. PubMed ID: 14673852
[TBL] [Abstract][Full Text] [Related]
15. Reactions of potent antitumor complex trans-[Ru(III)Cl4(indazole)2]- with a DNA-relevant nucleobase and thioethers: insight into biological action.
Egger A; Arion VB; Reisner E; Cebrián-Losantos B; Shova S; Trettenhahn G; Keppler BK
Inorg Chem; 2005 Jan; 44(1):122-32. PubMed ID: 15627368
[TBL] [Abstract][Full Text] [Related]
16. Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.
Chen H; Parkinson JA; Morris RE; Sadler PJ
J Am Chem Soc; 2003 Jan; 125(1):173-86. PubMed ID: 12515520
[TBL] [Abstract][Full Text] [Related]
17. Binding of organometallic ruthenium(II) anticancer compounds to nucleobases: a computational study.
Gossens C; Tavernelli I; Rothlisberger U
J Phys Chem A; 2009 Oct; 113(43):11888-97. PubMed ID: 19791792
[TBL] [Abstract][Full Text] [Related]
18. Ruthenation of duplex and single-stranded d(CGGCCG) by organometallic anticancer complexes.
Liu HK; Wang F; Parkinson JA; Bella J; Sadler PJ
Chemistry; 2006 Aug; 12(23):6151-65. PubMed ID: 16807967
[TBL] [Abstract][Full Text] [Related]
19. DNA interactions of monofunctional organometallic ruthenium(II) antitumor complexes in cell-free media.
Novakova O; Chen H; Vrana O; Rodger A; Sadler PJ; Brabec V
Biochemistry; 2003 Oct; 42(39):11544-54. PubMed ID: 14516206
[TBL] [Abstract][Full Text] [Related]
20. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro.
Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK
Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
